The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA
occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for
ischemic stroke and who are recommended for long-term NOAC therapy.
The clinical investigation is a prospective, randomized, multicenter active control worldwide
trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device
("Device Group") and a commercially available NOAC medication ("Control Group"). The choice
of NOAC in the Control Group will be left to study physician discretion.